Revati Shreeniwas has been appointed Chief Medical Officer of Aspen Neuroscience to advance the company’s cell therapy for Parkinson’s disease, enhancing its commercial readiness.
Aspen Neuroscience, a clinical-stage biotechnology company, has announced the appointment of Revati Shreeniwas as Chief Medical Officer (CMO). Her role will focus on accelerating the late-stage development and commercial readiness of the company’s innovative cell therapy for Parkinson’s disease.
This leadership change is part of Aspen’s strategy to transition its programs from clinical trials to market with integrity and purpose. The San Diego-based company is pioneering autologous regenerative therapies aimed at addressing neurodegenerative diseases.
Dr. Shreeniwas brings a wealth of experience to her new position, having received her medical education from Armed Forces Medical College in Pune, India. She possesses extensive expertise in neuromuscular and central nervous system (CNS) diseases, orphan indications, cardiovascular and respiratory diseases, as well as gene therapy.
With over 20 years of experience in the biopharma industry, Dr. Shreeniwas is a board-certified physician executive who has held multiple roles as CMO. She has a proven track record of advancing clinical programs from pre-Investigational New Drug (IND) applications through to registration, successfully navigating global regulatory pathways, and shaping clinical and medical strategies for venture-backed companies.
Throughout her career, she has designed and led more than 40 global clinical trials, including registrational studies. Her contributions have been pivotal in the approval and commercialization of several notable therapies, including Rytary for Parkinson’s disease, Sunosi for sleep disorders, Esbriet for idiopathic pulmonary fibrosis (IPF), and Tracleer for pulmonary hypertension.
Expressing her enthusiasm for her new role, Dr. Shreeniwas stated, “Aspen’s autologous iPSC-derived approach is redefining what’s possible in neurodegenerative disease. I’m excited to help deliver a rigorous registrational program for Parkinson’s patients, partnering across clinical, regulatory, technical operations, and medical affairs.”
Before joining Aspen, Dr. Shreeniwas held senior clinical positions at several biopharmaceutical companies, including Cystetic Medicines, Excision BioTherapeutics, Bright Minds Biosciences, and Soleno Therapeutics. She has also held faculty appointments at prestigious institutions such as Columbia University and Stanford University.
Aspen’s investigational therapy, ANPD001, is recognized as the most advanced autologous cell therapy in the United States for the treatment of Parkinson’s disease. The company’s personalized approach eliminates the need for immunosuppressive (IS) drugs, which are typically required to mitigate the body’s immune response against foreign cells. This innovative strategy aims to reduce IS-associated adverse events, eliminate IS drug-monitoring requirements, and facilitate dosing for patients who have contraindications to IS therapies.
ANPD001 has received Fast Track designation from the U.S. Food and Drug Administration (FDA), highlighting its potential significance in treating Parkinson’s disease. The ASPIRO trial, which is the first multi-patient, multi-center clinical trial of an autologous cell therapy for this condition, is currently underway. It is evaluating the safety, tolerability, and preliminary efficacy of ANPD001 in levodopa-responsive patients aged 50 to 70. Primary endpoints are expected to be reported at 12 months, with long-term follow-up extending up to 15 years.
This strategic appointment of Dr. Shreeniwas is expected to significantly enhance Aspen Neuroscience’s efforts in bringing innovative solutions to patients suffering from Parkinson’s disease, according to The American Bazaar.